OGN – organon & co. (US:NASDAQ)
Stock Stats
News
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
Organon & Co. (NYSE:OGN) had its price target raised by analysts at Barclays PLC from $7.50 to $8.00. They now have an "underweight" rating on the stock.
Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% [Yahoo! Finance]
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
Organon & Co. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Form 4 Organon & Co. For: Feb 27 Filed by: Falcione Aaron
Form 4 Organon & Co. For: Feb 27 Filed by: WALSH MATTHEW M
Form 4 Organon & Co. For: Feb 27 Filed by: Nisita Vittorio
Form 4 Organon & Co. For: Feb 27 Filed by: Stahler Rachel A
Form 4 Organon & Co. For: Feb 27 Filed by: Weaver Kirke
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.